- Stocks
- Pharma & Healthcare
- Gujarat Kidney And Super Speciality
Gujarat Kidney And Super Speciality share price
NSE: GKSLPharma & HealthcareMedical Care Facilities
Gujarat Kidney And Super Speciality at a glance
Gujarat Kidney And Super Speciality (NSE: GKSL) closed at ₹183.00 on 22 Oct 2026, up 0.53% on the day. With a market capitalisation of ₹1,443 Cr, it ranks 1283rd by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Medical Care Facilities.
At its last close the stock traded at 73.5× trailing earnings, against a return on equity of 36.3% in FY25. Its 52-week range is ₹98.36 (23 Jan 2026) to ₹209.80 (1 Oct 2026); the last close is 12.8% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹31 Cr (+212.7% year on year) and net profit ₹5 Cr (+263.2%), on a consolidated basis. Promoters held 71.45% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹1,443 CrRank 1283 on NSE
- P/E (trailing)
- 73.5×
- Price to book
- 0×FY25
- EPS (TTM)
- ₹2.65to Q4 FY26
- ROE
- 36.3%FY25
- ROCE
- 39.9%FY25
- Debt to equity
- 0.15FY25
- Net profit margin
- 23.6%FY25
- Book value / share
- ₹4.56FY25
- 52-week high
- ₹209.801 Oct 2026
- 52-week low
- ₹98.3623 Jan 2026
- RSI (14-day)
- 52.6
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | +0.53% | −5.7% | 0.0% | +43.1% | — |
Gujarat Kidney And Super Speciality quarterly results
| Quarter | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|
| Revenue | ₹12 Cr | ₹10 Cr | ₹15 Cr | ₹13 Cr | ₹23 Cr | ₹31 Cr |
| Revenue YoY | — | — | — | — | +97.2% | +212.7% |
| Net profit | ₹3 Cr | ₹1 Cr | ₹5 Cr | ₹3 Cr | ₹4 Cr | ₹5 Cr |
| Net profit YoY | — | — | — | — | +46.1% | +263.2% |
| Net margin | 21.5% | 13.6% | 35.4% | 22.3% | 16.0% | 15.8% |
| EPS | ₹0.52 | ₹0.25 | ₹0.85 | ₹0.47 | ₹0.52 | ₹0.81 |
Gujarat Kidney And Super Speciality financials
| Item | FY23 | FY24 | FY25 |
|---|---|---|---|
| Revenue | ₹0 Cr | ₹5 Cr | ₹40 Cr |
| Operating profit | −₹0 Cr | ₹2 Cr | ₹13 Cr |
| Net profit | −₹0 Cr | ₹2 Cr | ₹10 Cr |
| EPS (₹) | ₹0.00 | ₹0.00 | ₹2.00 |
| Cash from operations | ₹0 Cr | ₹1 Cr | ₹14 Cr |
| Total debt | ₹0 Cr | ₹2 Cr | ₹2 Cr |
| Shareholders' equity | ₹0 Cr | ₹11 Cr | ₹26 Cr |
Gujarat Kidney And Super Speciality shareholding pattern
| Holder | 29 Dec 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|
| Promoters | 71.45% | 71.45% | 71.45% | 71.45% |
| Foreign institutions | 13.09% | 10.47% | 4.88% | 4.88% |
| Domestic institutions | 7.84% | 1.67% | 0.56% | 0.56% |
| Non-institutions | 7.62% | 16.40% | 23.10% | 23.10% |
Gujarat Kidney And Super Speciality vs peers
The listed Pharma & Healthcare companies nearest to Gujarat Kidney And Super Speciality by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| ASTECAstec LifeSciences | ₹700.20 | +6.41% | −5.5% | ₹1,560 Cr | — | — |
| SURAKSHASuraksha Diagnostic | ₹294.05 | +1.75% | +1.1% | ₹1,531 Cr | 47.6 | — |
| GKSLGujarat Kidney And Super Speciality | ₹183.00 | +0.53% | — | ₹1,443 Cr | 73.5 | — |
| AMRUTANJANAmrutanjan Health Care | ₹496.20 | +0.45% | −29.1% | ₹1,435 Cr | 24.8 | — |
| JAGSNPHARMJagsonpal Ser | ₹216.03 | −1.13% | +2.0% | ₹1,422 Cr | 34.2 | — |
| TTKHLTCARETTK Healthcare | ₹994.70 | +3.29% | −11.6% | ₹1,406 Cr | 21.4 | — |
| FERMENTAFermenta Biotech | ₹466.35 | −0.78% | — | ₹1,373 Cr | — | — |
Ask anything about Gujarat Kidney And Super Speciality
Pivot answers on the live chart with evidence you can check, and tests strategies against GKSL's own history. Try: “Why has GKSL moved over the last three months?” · “Backtest a 50-day moving-average crossover on GKSL over five years” · “Compare GKSL with ASTEC on margins and valuation”
Frequently asked questions about Gujarat Kidney And Super Speciality
What is the share price of Gujarat Kidney And Super Speciality today?
Gujarat Kidney And Super Speciality (NSE: GKSL) last closed at ₹183.00 on 22 Oct 2026. Its 52-week high is ₹209.80 and its 52-week low is ₹98.36.
What is the market cap of Gujarat Kidney And Super Speciality?
Gujarat Kidney And Super Speciality's market capitalisation is ₹1,443 Cr (₹1,443 Cr) at the 22 Oct 2026 close, ranking 1283rd among the NSE companies Pivot tracks.
What is the P/E ratio of Gujarat Kidney And Super Speciality?
Gujarat Kidney And Super Speciality trades at a trailing P/E of 73.5. The median P/E of the 4 closest Pharma & Healthcare peers by market cap is 34.2.
What is the ROE and ROCE of Gujarat Kidney And Super Speciality?
Return on equity was 36.3% in FY25 and return on capital employed was 39.9% in FY25 (consolidated figures).
Is Gujarat Kidney And Super Speciality a debt-free company?
No. Gujarat Kidney And Super Speciality's debt-to-equity ratio was 0.15 in FY25, with total debt of ₹2 Cr.
What were Gujarat Kidney And Super Speciality's latest quarterly results?
For Q4 FY26 (quarter ended 31 Mar 2026), Gujarat Kidney And Super Speciality reported revenue of ₹31 Cr, +212.7% year on year, and net profit of ₹5 Cr, +263.2% year on year.
What is the shareholding pattern of Gujarat Kidney And Super Speciality?
As of 30 Jun 2026: promoters 71.45%, foreign institutions 4.88%, domestic institutions 0.56%, non-institutions 23.10%.
Who are Gujarat Kidney And Super Speciality's competitors?
The listed Pharma & Healthcare companies closest to Gujarat Kidney And Super Speciality by market cap are Astec LifeSciences, Suraksha Diagnostic, Amrutanjan Health Care, Jagsonpal Ser, TTK Healthcare and Fermenta Biotech.
Is Gujarat Kidney And Super Speciality a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Gujarat Kidney And Super Speciality's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on GKSL against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with G · all NSE stocks · this page as text